Carcinoid Syndrome - Pipeline Insight, 2021

SKU ID :DEL-17687661 | Published Date: 15-Mar-2021 | No. of pages: 60
Introduction Executive Summary Carcinoid Syndrome: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Carcinoid Syndrome – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Carcinoid Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends Carcinoid Syndrome Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Early Stage Products (Phase I) • Comparative Analysis Paltusotine: Crinetics Pharmaceuticals • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products • Comparative Analysis AQST-305: Aquestive Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Carcinoid Syndrome Key Companies Carcinoid Syndrome Key Products Carcinoid Syndrome- Unmet Needs Carcinoid Syndrome- Market Drivers and Barriers Carcinoid Syndrome- Future Perspectives and Conclusion Carcinoid Syndrome Analyst Views Carcinoid Syndrome Key Companies Appendix
Table 1 Total Products for Carcinoid Syndrome Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products
• Aquestive Therapeutics • Crinetics Pharmaceuticals
  • PRICE
  • $1500
    $4500

Our Clients